摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-aza-bicyclo[3.1.0]hex-6-ylamine

中文名称
——
中文别名
——
英文名称
3-aza-bicyclo[3.1.0]hex-6-ylamine
英文别名
6-amino-3-azabicyclo[3.1.0]hexane;6-amino-3-azabicyclo [3. 1.0] hexane;3-azabicyclo[3.1.0]hex-6-ylamine;3-azabicyclo[3.1.0]hexan-6-amine;3-azabicyclo[3.1.0]hexyl-6-amine
3-aza-bicyclo[3.1.0]hex-6-ylamine化学式
CAS
——
化学式
C5H10N2
mdl
——
分子量
98.1478
InChiKey
MNUHYQZBNHDABI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1
  • 重原子数:
    7
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    38
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AZABICYCLO [3.1.0] HEXANE 3,6-DISUBSTITUES UTILISES COMME ANTAGONISTES DU RECEPTEUR MUSCARINIQUE
    申请人:RANBAXY LAB LTD
    公开号:WO2004052857A1
    公开(公告)日:2004-06-24
    The invention relates to derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
    这项发明涉及结构为(I)的3,6-二取代的氮杂双环[3.1.0]己烷衍生物。本发明的化合物可以作为肌碱受体拮抗剂,可用于治疗通过肌碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。该发明还涉及含有本发明化合物的药物组合物以及治疗通过肌碱受体介导的疾病的方法。
  • [EN] SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AZABICYCLO HEXANE SUBSTITUES EN TANT QU'ANTAGONISTES DE RECEPTEURS MUSCARINIQUES
    申请人:RANBAXY LAB LTD
    公开号:WO2004069835A1
    公开(公告)日:2004-08-19
    This invention relates to derivatives of substituted azabicyclo hexanes.The compound of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.The invention also relates to a process for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
    这项发明涉及取代的氮杂环己烷衍生物。本发明的化合物可以作为肌碱受体拮抗剂发挥作用,并可用于治疗通过肌碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。该发明还涉及制备本发明化合物的方法、含有本发明化合物的药物组合物以及治疗通过肌碱受体介导的疾病的方法。
  • Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
    作者:Leslie W. Tari、Michael Trzoss、Daniel C. Bensen、Xiaoming Li、Zhiyong Chen、Thanh Lam、Junhu Zhang、Christopher J. Creighton、Mark L. Cunningham、Bryan Kwan、Mark Stidham、Karen J. Shaw、Felice C. Lightstone、Sergio E. Wong、Toan B. Nguyen、Jay Nix、John Finn
    DOI:10.1016/j.bmcl.2012.11.032
    日期:2013.3
    The bacterial topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE) are essential enzymes that control the topological state of DNA during replication. The high degree of conservation in the ATP-binding pockets of these enzymes make them appealing targets for broad-spectrum inhibitor development. A pyrrolopyrimidine scaffold was identified from a pharmacophore-based fragment screen with optimization
    细菌拓扑异构酶DNA回旋酶(GyrB)和拓扑异构酶IV(ParE)是在复制过程中控制DNA拓扑状态的必需酶。这些酶在ATP结合袋中的高度保守性使其成为广谱抑制剂开发的诱人靶标。从基于药效基团的片段筛选中鉴定出具有最佳潜力的吡咯并嘧啶骨架。使用选定的GyrB / ParE直系同源物进行的抑制剂复合物的结构表征有助于鉴定靶标ATP结合口袋中的重要空间,动态和组成差异,从而可以设计具有宽酶谱和双重靶向活性的高效吡咯并嘧啶抑制剂。
  • [EN] AZA-BICYCLOHEXYL SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] DÉRIVÉS D'INDOLYLALKYLAMINO SUBSTITUÉS PAR AZA-BICYCLOHEXYLE COMME NOUVEAUX INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2009118370A1
    公开(公告)日:2009-10-01
    This invention comprises the novel compounds of Formula (I), wherein R1, R2, R3, R4, A and X have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.
    这项发明涵盖了具有组成式(I)的新型化合物,其中R1、R2、R3、R4、A和X具有定义的含义,具有组蛋白去乙酰化酶抑制酶活性;它们的制备、含有它们的组合物以及它们作为药物的用途。
查看更多